Journal of Clinical Oncology
Articles in this Issue
Epidemiology, clinical outcomes, and healthcare resource utilization in non-Hodgkin’s lymphoma patients with protein-energy malnutrition hospitalized for acute congestive heart failure: A comprehensive population-based study.
e19053 Background: Patients with non-Hodgkin's lymphoma (NHL) are at heightened risk of heart failure due to the cardiotoxic effects of chemotherapy, espe...
Improving adherence to cancer care for socioeconomically disadvantaged patients with central nervous system tumors.
2033 Background: Socially disadvantaged patients often face significant barriers to adhering to and completing cancer trea...
Investigating the impact of COVID-19 on septicemias, healthcare-associated complications, and mortality in patients with cancers of the lip, oral cavity, and pharynx (CLOP) in the United States.
e18041 Background: The COVID-19 pandemic has significantly affected various patient populations, including those with cancer. We hypothesize that CLOP pat...
Perioperative pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Asia versus non-Asia subgroup analysis of KEYNOTE-585.
4194 Background: In the randomized phase 3 KEYNOTE-585 study (NCT03221426), pCR was significantly improved in participants (pts) with locally advanced G/G...
Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).
8585 Background: Despite advancements in third line treatments, long-term survival for advanced non-small cell lung cancer (NSCLC) remains suboptimal, wit...
Real-world evidence on recurrence risk from clinicopathologic features in HR+/HER2− early breast cancer patients using Chinese electronic health records.
e13085 Background: The NATALEE trial demonstrated the benefits of ribociclib based treatment in a broad population with HR+/HER2− early breast cancer (eBC...
Towards a shared understanding of the concept of cure in early-stage treatment of solid tumors.
e13866 Background: Advancement in early-stage solid tumor treatments, notably with potentially curative therapies in (neo)adjuvant settings, underscores t...
Comparative effectiveness of delivering early palliative care via video versus in-person on end-of-life outcomes in patients with advanced lung cancer.
1649 Background: Findings from our prior large-scale comparative effectiveness trial showed the equivalent effect of delivering early palliative care via...
Evaluation of daratumumab for treating multiple myeloma in patients with high-risk cytogenetic factors: A pooled analysis using synthetic individual patient data.
e19554 Background: Adding daratumumab to standard multiple myeloma (MM) regimens improves response rates and clinical outcomes. Systematic reviews (meta-a...
Detecting hotspots of intra- and transchromosomal fusions in liposarcomas by RNA sequencing.
11561 Background: Liposarcoma (LPS) is characterized by unstable genomes and high occurrence of gene fusions. Hotspots of both recurrent and non-recurrent...
A phase 3 randomized study of ASP-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in locoregional recurrent head and neck squamous cell carcinoma (HNSCC).
TPS6122 Background: Recurrent (r) HNSCC carries a poor prognosis and a low survival rate. Locoregional (LR) progression significantly contributes to both...
Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes.
5538 Background: Therapeutic cancer vaccines combined with immune checkpoint inhibitors offer a promising strategy to enhance anti-tumor responses. We rec...
A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy.
8551 Background: Interleukin-12 (IL-12) is a cytokine that enhances anti-tumor immunity via interferon-gamma release and has demonstrated synergistic effe...
Real-world safety and effectiveness of avelumab in immune-compromised (IC) and non-IC patients with Merkel cell carcinoma (MCC): Results from a prospective German registry (MCC-TRIM).
9543 Background: MCC is a rare and aggressive form of skin cancer. Avelumab was the first immunotherapy approved for patients with metastatic MCC in Europ...
Exclusion of people from oncology clinical trials based on functional status and other criteria.
e23002 Background: To improve equity in cancer care, oncology clinical trials should include populations experiencing health care disparities, including p...
Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with <i>KRAS G12D</i> mutations.
TPS3178 Background: KRAS G12D is the most common KRAS mutation...
First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.
e17548 Background: Low-grade serous ovarian cancer (LGSOC), a rare ovarian malignancy, exhibits a very limited responsiveness to chemotherapy. There is a...
Lung cancer screening in high-risk never-smokers with artificial intelligence (LC-SHIELD study).
8055 Background: Approximately 50% of Asian lung cancer patients are never smokers. Screening with low-dose computed tomography (LDCT) of thorax in high-r...
Impact of proximity to health center on adherence to NCCN guidelines in patients with soft tissue sarcomas.
e13503 Background: Soft tissue sarcomas (STS) are a rare malignancy, approximately 13,590 new cases are diagnosed annually in the United States. Due to th...
Clinical utility of germline genetic testing in diverse cancer types.
10590 Background: Germline genetic testing (GGT) is often recommended for cancer patients with an estimated ≥10% risk of carrying a clinically actionable...
Pathologic response and safety of neoadjuvant pembrolizumab with or without entinostat in muscle-invasive urothelial cancer (MIUC).
4603 Background: Entinostat (Ent) is a selective histone deacetylase 1/3 inhibitor that potentiates immune checkpoint inhibitor activity in immunocompeten...
INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.
TPS2683 Background: Immunotherapy is an established cancer therapy, although mechanisms of non-response & resistance are emerging, leaving few options...
Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts.
e20597 Background: Immunotherapy has transformed non-small cell lung cancer (NSCLC) outcomes, with pivotal trials like IMpower010, PACIFIC, and KEYNOTE 18...
Analysis of genomic and immune microenvironment differences in Chinese populations: Revealing potential mechanisms of poor immunotherapy outcomes in patients with EGFR mutation and ALK fusion non-small cell lung cancer.
8565 Background: Non-small cell lung cancer (NSCLC) patients with EGFR mutations or ALK fusions often exhibit suboptimal responses to immunotherapy, yet t...
The effect of health co-morbidities on outcomes in patients with multiple myeloma.
e19529 Background: Multiple Myeloma is a hematological malignancy that occurs when plasma cells become cancerous. Patients with multiple myeloma are typic...